**Author details**

Avani Athauda and Ian Chau\* The Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom

\*Address all correspondence to: Ian.chau@rmh.nhs.uk

© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**15**

*Advances in Molecular Subclassification of Colorectal Cancer*

rectal cancer. Nature. 2012;**487**:330-337.

[9] Roepman P, Schlicker A, Tabernero J, Majewski I, Tian S, Moreno V, et al. Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-tomesenchymal transition. International Journal of Cancer. 2014;**134**:552-562.

[10] De Sousa E Melo F, Wang X, Jansen M, Fessler E, Trinh A, de Rooij LPMH, et al. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nature Medicine. 2013;**19**:614-618. DOI: 10.1038/nm.3174

[11] Marisa L, de Reyniès A, Duval A, Selves J, Gaub MP, Vescovo L, et al. Gene expression classification of colon cancer into molecular subtypes: Characterization, validation, and prognostic value. PLoS Medicine. 2013;**10**:e1001453. DOI: 10.1371/

[12] Schlicker A, Beran G, Chresta CM, McWalter G, Pritchard A, Weston S, et al. Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines. BMC Medical Genomics. 2012;**5**:66. DOI: 10.1186/1755-8794-5-66

[13] Budinska E, Popovici V, Tejpar S, D'Ario G, Lapique N, Sikora KO, et al. Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer. The Journal of Pathology. 2013;**231**:63-76. DOI:

[14] Sadanandam A, Lyssiotis CA, Homicsko K, Collisson EA, Gibb WJ, Wullschleger S, et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nature Medicine. 2013;**19**:619-

625. DOI: 10.1038/nm.3175

DOI: 10.1038/nature11252

DOI: 10.1002/ijc.28387

journal.pmed.1001453

10.1002/path.4212

*DOI: http://dx.doi.org/10.5772/intechopen.80679*

[1] Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M,

[2] Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis.

[3] Müller MF, Ibrahim AEK, Arends MJ. Molecular pathological classification of colorectal cancer. Virchows Archiv. 2016;**469**:125-134. DOI: 10.1007/

[4] Marzouk O, Schofield J. Review of histopathological and molecular prognostic features in colorectal cancer. Cancers. 2011;**3**:2767-2810. DOI:

[5] Sanchez JA, Krumroy L, Plummer S, Aung P, Merkulova A, Skacel M, et al. Genetic and epigenetic classifications define clinical phenotypes and determine patient outcomes in colorectal cancer. British Journal of Surgery. 2009;**96**:1196-

[6] Tran B, Kopetz S, Tie J, Gibbs P, Jiang Z-Q, Lieu CH, et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer. 2011;**117**:4623-4632.

[7] Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. The New England Journal of Medicine. 2015;**372**:2509-2520. DOI: 10.1056/

et al. Genetic alterations during colorectal-tumor development. New England Journal of Medicine. 1988;**319**:525-532. DOI: 10.1056/

NEJM198809013190901

Cell. 1990;**61**:759-767. DOI: 10.1016/0092-8674(90)90186-I

s00428-016-1956-3

10.3390/cancers3022767

1204. DOI: 10.1002/bjs.6683

DOI: 10.1002/cncr.26086

NEJMoa1500596

[8] Comprehensive molecular

characterization of human colon and

**References**

*Advances in Molecular Subclassification of Colorectal Cancer DOI: http://dx.doi.org/10.5772/intechopen.80679*
